The Toronto Stock Exchange reports that it is reviewing the Class A common shares of Appili Therapeutics Inc. with respect to meeting its requirements for continued listing. According to the TSX, the company has 120 days to regain compliance with the exchange's continued listing requirements, pursuant to the remedial delisting review process.
© 2026 Canjex Publishing Ltd. All rights reserved.